DR. AGARWAL’S HEALTH CARE LIMITED Successful completion of Initial Public Offering and listing on Bombay Stock Exchange and National Stock Exchange on February 4, 2025

Mumbai, February 17, 2025: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain(1) operating a network of 221 Facilities across 10 countries, today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2024. 

Highlights of the Quarter Ended December 31, 2024 (Q3 FY2025) 

• Revenue from Operations of INR 431 Cr, growth of 29.5% YoY
  • Revenue from Operations – India of INR 390 Cr, growth of 34.5% YoY
  • Revenue from Mature Facilities of INR 291 Cr, growth of 16.6% YoY
• EBITDA of INR 128 Cr, growth of 26.3% YoY with EBITDA margin of 28.8% 
• Profit after Tax of INR 28 Cr, growth of 25.0% YoY with PAT margin of 6.4% 
• 221 Facilities as of December 31, 2024
  • 12 Facilities have been added in Q3 FY2025 

Highlights for the Nine Months Ended December 31, 2024 (9M FY2025) 

• • Revenue from Operations of INR 1,251 Cr; growth of 27.2% YoY
    • Revenue from Operations – India of INR 1,124 Cr, growth of 31.7% YoY
    • Revenue from Mature Facilities of INR 874 Cr, growth of 15% YoY
  • Sale of Services(2) contributed 79.9% and Sale of Products(2) contributed 20.1% to revenue from operations
  • EBITDA of INR 356 Cr, growth of 27.5% YoY with EBITDA margins of 27.8% 
  • Profit after Tax of INR 68 Cr, growth of 26.2% YoY with profit after tax margins of 5.3% 

• 42 Facilities were added in 9M FY2025 

• • • Of these 35 new Facilities have been set up and seven Facilities have been acquired
• Performed 213,602 surgeries in 9M FY2025, growth of 31.8% YoY

Commenting on Q3 FY2025 and Nine Months ended December 31, 2024 results, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said:

“We are delighted to announce our maiden quarter performance post listing where we have delivered a robust growth of 29.5% in revenue and 26.3% in EBITDA. We have continued to witness strong growth in both patient footfalls and the number of surgeries performed. Our commitment to providing exceptional care, along with investments in cutting-edge technology, positions us for long-term success. While we have maintained our growth trajectory, we remain committed to delivering sustainable and steady growth in the coming quarters.”

Financial Highlights:

• By revenue from operations for FY24
• Services include Surgeries, Consultation, Treatments and Investigations; Products include Opticals, Contact Lens and Accessories, and Pharmaceutical Products